Pharmacokinetic behaviors of ligustrazine after single- and multiple-dose intravenous Shenxiong glucose injection in rats by high-performance liquid chromatography
- 24 Downloads
Shenxiong glucose injection (SXG) is a traditional Chinese medicine that is used for cardio-cerebral vascular diseases on the national essential drug list of China. To date, a comprehensive knowledge concerning the pharmacokinetic profile of SXG-related components, especially following multiple dosing, is still lacking. This study was designed to investigate the pharmacokinetics and tissue distribution of ligustrazine after single- and multiple-dose intravenous administration of SXG in rats. A simple HPLC method was developed for the determination of ligustrazine in biological samples. The pharmacokinetic profiles of ligustrazine in rats were linear after both single- and multiple-dose intravenous administration of SXG, with a half-life of approximately 35 min. Ligustrazine was readily distributed in highly perfused organs and almost eliminated from organs after 90 min of SXG injection. The AUC0-t and C0 of ligustrazine after SXG injection (18 ml/kg, equal to 9.0 mg/kg ligustrazine) were increased significantly compared to those of single ligustrazine administration (9.0 mg/kg), indicating that the pharmacokinetics of ligustrazine in the SXG were affected by other ingredients. This study provided first evidence for the pharmacokinetic characteristics of ligustrazine after both single and multiple-dose SXG in rats, which would be helpful for its clinical application.
KeywordsShenxiong glucose injection (SXG) Ligustrazine Pharmacokinetics Tissue distribution
Hong Nie, Qiong Wang, and Li Yu conceived and designed research. Qiong Wang, Huaping Sun, Li Yu, and Baoping Jiang conducted experiments. Qiong Wang, Huaping Sun, Xianpeng Ma, Changqiong Bi, and Yueheng Liu analyzed data. Qiong Wang, Hong Nie, Zhihua Wang, Qinghong Fan, and Yuan Yu wrote the manuscript. All authors read and approved the manuscript.
This work was supported by grants from the National Natural Science Foundation of China (No. 81673634) and the Peak Talent Foundation of Jiangsu Province Hospital of Chinese Medicine (y2014rc18, y2018rc20).
Compliance with ethical standards
Animal welfare and experimental procedures were strictly performed in accordance with the Guidelines for Animal Experimentation of Nanjing University of Chinese Medicine (Nanjing, China) and were in compliance with the Declaration of Helsinki.
Conflict of interest
The authors declare that they have no conflict of interest.
- Gerber F, Krummen M, Potgeter H, Roth A, Siffrin C, Spoendlin C (2004) Practical aspects of fast reversed-phase high-performance liquid chromatography using 3 microm particle packed columns and monolithic columns in pharmaceutical development and production working under current good manufacturing practice. J Chromatogr A 1036:127–133CrossRefGoogle Scholar
- Li Y, Wang Y, Tai W, Yang L, Chen Y, Chen C, Liu C (2015) Challenges and solutions of pharmacokinetics for efficacy and safety of traditional Chinese medicine. Curr Drug Metab 16:765–776Google Scholar
- Liao F, Jiao L (2000) Ligustrazine, allicin and shear-induced platelet aggregation. Clin Hemorheol Microcirc 22:167–168Google Scholar
- Zheng L, Gong Z, Lu Y, Xie Y, Huang Y, Liu Y, Lan Y, Wang A, Wang Y (2015) A UPLC-MS/MS method for simultaneous determination of danshensu, protocatechuic aldehyde, rosmarinic acid, and ligustrazine in rat plasma, and its application to pharmacokinetic studies of Shenxiong glucose injection in rats. J Chromatogr B Anal Technol Biomed Life Sci 997:210–217CrossRefGoogle Scholar